Richard F. Lockey, M.D.



Professor of Medicine, Pediatrics and Public Health
Distinguished University Health Professor
Joy McCann Culverhouse Chair in Allergy and Immunology
Director, Division of Allergy and Immunology
University of South Florida College of Medicine
James A. Haley Veterans' Hospital

Clinical Research Unit: Mailing Address	University of South Florida (1975-present) Asthma, Allergy & Immunology Clinical Research Unit 13801 Bruce B. Downs Blvd., Suite 505, Tampa, FL 33613 Phone: 813.631.4024 Fax: 813.631.4030
University of South Florida College of Medicine and James A. Haley VA: Hospital Mailing Address	University of South Florida College of Medicine Division of Allergy and Immunology c/o V.A. Hospital 13000 Bruce B. Downs. Blvd. (111D) Tampa, Florida 33612 Phone: 813.972.7631 Fax: 813.910.4041
Drs. Lockey, Fox, Ledford, Glaum Clinic: Mailing Address	13801 Bruce B. Downs Blvd., Suite 502 Tampa, FL 33613 Phone: 813.971.9743 Fax: 813.558.9421
Professional Education	Haverford College, Haverford, Pennsylvania, B.S., 1961. Temple University School of Medicine, Philadelphia, Pennsylvania, M.D., 1965 (Alpha Omega Alpha) University of Michigan, Ann Arbor, Michigan, M.S., 1972.

Professional Experience

Joy McCann Culverhouse Chair in Allergy and Immunology – July, 1997-present.

Professor of Pediatrics, University of South Florida College of Medicine, All Children's Hospital, St. Petersburg Campus, St. Petersburg, Florida, July, 1987-present.

Professor of Public Health, University of South Florida College of Public Health, Tampa, Florida, July, 1987-present.

Professor of Medicine, University of South Florida College of Medicine, Tampa, Florida, July, 1983-present.

Director, Division of Allergy and Immunology, University of South Florida College of Medicine, Tampa, FL, July, 1982-present.

Chief, Section of Allergy and Immunology, James A. Haley Veterans' Hospital, Tampa, Florida, July, 1982 – January, 2016.

Assistant Director, Division of Allergy and Immunology, University of South Florida College of Medicine, Tampa, Florida, July, 1979-June, 1982.

Associate Professor of Medicine, University of South Florida College of Medicine, Tampa, Florida, July 1977-June, 1983.

Assistant Chief, Section of Allergy and Immunology, James A. Haley Veterans' Hospital, Tampa, Florida, July, 1973-June, 1982.

Assistant Professor of Medicine, University of South Florida College of Medicine, Tampa, Florida, March, 1973-June, 1977.

Chief, Allergy and Immunology, Major USAF, Carswell AFB Hospital, Fort Worth, Texas, Jan., 1971-Dec., 1972.

Fellow in Allergy and Immunology, University Hospital, University of Michigan, Ann Arbor, Michigan, January, 1969 - December, 1970. This includes a year of graduate training at the University of Michigan Graduate School.

Resident, Internal Medicine, University Hospital, University of Michigan, Ann Arbor, Michigan, July, 1966-Dec., 1968.

Assistant Resident, Internal Medicine, University Hospital, University of Michigan, Ann Arbor, Michigan, 1966-1967.

Straight Medical Intern, Temple University Medical School, Philadelphia, Pennsylvania, July, 1965-June, 1966.

Licensure

Florida, # ME 19662.
Pennsylvania, # MD 014057-E

Certification

American Board of Internal Medicine, 1970.
American Board of Allergy and Immunology, 1974.

Professional Memberships

1. American Academy of Allergy and Immunology, Fellow.
   President, 1992-1993.
   President-Elect, 1991-1992.
   Treasurer, 1990-1991.
   Secretary, 1989-1990.
   Historian, 1988-1989.
   Chairperson, Finance Committee, 1993-1994.
   Member, Finance Committee, 1989-1995.
   Member, Board of Directors, 1985-1995.

State and Local Public and Community Committees

1. Public elected official, Board of Trustees, Carrollwood Recreation District, Tampa, Florida, 1973-1975.
2. Member, Board of Trustees, Lancaster County Asthma and Allergy Foundation (non profit organization to support research in allergic and immunologic diseases), 1984-present.
3. Hillsborough County Public Education Advisory AIDS Committee, 1985-1986.
4. Founder, Board Member, and Medical Advisor, Central Florida Chapter (now Unit), Asthma and Allergy Foundation of America, 1984-1987.
5. Founder, Board Member, and Medical Advisor, Florida Chapter, Asthma and Allergy Foundation of America, 1986-present.
6. President, 1989-1990, Medical Advisor, 1986-1998.
7. Tampa Preparatory School AIDS Committee, Tampa, Florida, 1987-1989.
8. Member, Medical Advisory Council, Florida Chapter, National Hemophilia Foundation, 1990-1991.
9. Associate Member, USF Institute for Systematic Botany, 1990-1992.
10. Member, Medical Advisory Panel, Museum of Science and Industry, Tampa, Florida, 1994.
11. Florida Cross/Blue Shield Advisory Panel, Member, 1996 - 1997.
12. Member, Professional Education & Research Committee, American Lung Association of Florida, Jacksonville, Florida, 2001.
13. American Lung Association, Walk with the Animals Benefiting Asthma

Research, Busch Gardens, May 18, 2002.

14. Member, American Lung Association of Florida, ALAF Research Subcommittee, 2004.

15. ALK Allergen Immunotherapy Consultants Group, Chairman, 1994 – 2000.

16. American Lung Association, Tampa Bay Community Advisory Group, Member, 1998.

17. American Lung Association of Florida, Research Subcommittee, Member, 2004 .

18. Member of the Board, Hillsborough County Medical Association, Inc., Tampa, FL, May 8, 2013 – May 8, 2014.

19. Executive Council – USF Dist, Hillsborough County Medical Association, 2013 – 2015.

National Advisory Committees

1. Sub-committees Member, Asthma and Allergy Foundation of America (AAFA) Medical Scientific Council, 2015 -:
    - Asthma
    - Allergic Rhinoconjunctivitis/Sinusitis
    - Urticaria/Angjioedema

U.S. Government Committees

1. Allergenic Products Advisory Committee, Food and Drug Administration, Department of Health and Human Services, 1985-1989.

2. NIH Task Force on Guidelines for Clinical Investigation of Nonbroncho-dilating Anti-asthmatic Drugs, American Academy of Allergy and Immunology, 1985.

3. NIH Task Force on Guidelines for Standardizing Old and New Technologies Used for Diagnosis and Treatment of Allergic Skin and Respiratory Diseases, Washington, D.C., June 18-19, 1987, "Immediate Skin Tests".

4. Veteran's Administration Panel on Respiratory Disabilities' Rating Schedule, Bethesda, Maryland, May 1 & 2, 1991.

5. National Heart, Lung and Blood Institute (NHLBI) / American Academy of Allergy, Asthma and Immunology (AAAAI) / American Thoracic Society (ATS) - Asthma Phenotype Task Force, 2006 -.

International Committees

1. International Union of Immunologic Societies, Steering Committee of the Allergen Standardization Subcommittee, 1986-1987.

2. United Nations Environment Programme, Aerosols Technical Options Committee, 1993-1995.

3. International Association of Allergology and Clinical Immunology (IAACI), the European Academy of Allergology and Clinical Immunology (EAACI), the American Academy of Allergy, Asthma and Immunology (AAAAI), and the European Respiratory Society (ERS) Chairman, Advisory Board, *Global Aspects of Allergy & Immunology,* 1996-1998.

4. Co-Chair, World Health Organization (WHO) "Position Paper – Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases", 1997-1998.

5. Allergic Rhinitis and its Impact on Asthma (ARIA), Executive Committee & Advisory Committee member, 1999.

6. World Allergy Organization (WAO) [International Association of Allergology and Clinical Immunology (IAACI)], Board Member, 1998.

7. Member, World Allergy Organization, (WAO) and World Health Organization, (WHO) Committee on "Prevention of Allergy and Asthma", 2000-2005.

8. Working Member, World Health Organization, (WHO) Committee on "Allergic Rhinitis and its Impact on Asthma (ARIA)", 1995.

9. International Advisor, International Symposium on Basic Approach to Allergic Rhinitis (ISBAAR), 2000.

10. International Advisory Committee; World Congress on Immunopathology, USA; Congress Secretariat 16/10 Miklukho-Maklaya Street, 117997 Moscow, Russia. 1999 – 2003.

11. Chair, Audit and Finance Committee, World Allergy Organization (WAO), 2004-2007.

12. Co-Chair, Bylaws Committee, World Allergy Organization (WAO), 1998-2009.

13. Chair, Communication Council, World Allergy Organization (WAO), 2002-2009.

9. Member, Awards Committee, World Allergy Organization (WAO), 2006-present.

10. Member, Congress Council, World Allergy Organization (WAO), 2006.

11. Member, Education Council, World Allergy Organization (WAO), 2006.

12. Member, GLORIA Advisory Board, 2006.

13. Member, US GLORIA Advisory Board, 2006.

14. Member, Nomenclature Committee, 2000-2004.

15. Member, Nominating Committee, World Allergy Organization (WAO), 2006.

16. Member, Congress Organizing Committee, World Allergy Organization (WAO),

2006-present.

17. Co-Chair, WAO Audit and Finance Committee, 2008-2009.

18. Vice-Chair, WAO Awards Committee, 2008-2009.

19. Vice-Chair, WAO Congress Council, 2008-2009

20. Honorable Member, Latin-American Society of Allergy, Asthma and Immunology (SLAAI), 2006.

University & VA Service

1. President's Council, University of South Florida, Tampa, Florida, 1972-present.

2. University of South Florida, Tampa, Florida, Board of Directors, 1987-1988.

3. Student Advisor, University of South Florida College of Medicine, Tampa, Florida, 1982-1987.

4. University of South Florida Athletic Department, Team Physician, 1985.

5. University of South Florida Committee on AIDS, Tampa, Florida, 1987-1990.

6. James A. Haley Veterans' Hospital AIDS Advisory Committee, Tampa, Florida, 1987-1990.

7. University of South Florida Medical Center AIDS Committee, Tampa, Florida, 1987-1990.

8. University of South Florida College of Medicine, Charge to the Graduation Class of 1987, Tampa, Florida, May 30, 1987, "ave Atque Vale".

9. University of South Florida College of Medicine, Graduate Medical Education Council, 1987.

10. Hillsborough County Medical Association/University of South Florida College of Medicine Liaison Committee, Tampa, Florida, 1988-1991.

11. Committee for the Protection of Animals in Research, 1987.

12. University of South Florida College of Medicine Committee on Bylaws, Tampa, Florida, 1991-1993.

13. Chairman, Andor Szentivanyi, M.D., D.Sc., Emeritus Dean of University of South Florida College of Medicine, USF Recognition Dinner, 1993.

14. Co-Host, Reception for USF Athletic Department, at University of South Florida College of Medicine, Tampa, Florida, October 30, 1991.

15. University of South Florida Committee to Study the Feasibility of Football, Fall, 1991.

16. Student Advisement Program for Clinical Students, University of South Florida College of Medicine, Tampa, Florida, 1994.

17. Chairman, Roy H. Behnke, M.D., Gala Committee, 1995-1996, University of South Florida College of Medicine, Raised approximately $150,000.00 for the Roy H. Behnke Endowed Lectureship.

18. Speaker, The Florida Diagnostic and Learning Resources System at the University of South Florida - FDLRS Days (Conference), Holiday Inn Busch Gardens, Tampa, Florida, May 10-12, 1995. "Allergic Diseases and Asthma."

19. Member, University of South Florida College of Medicine, LCME Self-Study Committee on Research (Liaison Committee of Medical Education), 1998.

20. Member, Clinical Research Committee, University of South Florida College of Medicine, 1993-1997.

21. Member, Green and Gold Committee, University of South Florida College of Medicine Environment Research, 1998.

22. Member, Search Committee for the Good Chair, 2001.

23. Chairman: "A Tribute to Robert A. Good, MD, PhD", February 10, 2001. Raised approximately $150,000.00 for the Robert A. Good Endowed Lectureship.

24. Chairman: '200' Year Celebration for Samuel Bukantz, M.D.", September 7, 2001.

25. Member, Lewis Barness, M.D. Tribute Committee, February 2002. Raised approximately $100,000 for the Lew Barness Endowed Lectureship.

26. Member, Faculty Senate, of the University of South Florida College of Medicine, 2002-2004.

27 Member, Clinical Research Committee, University of South Florida Health Sciences Center, 2003.

28. Member, Gary Litman PhD 2003-2004 Distinguished University Professor, Discipline Committee, 2004.

29. Speaker, University of South Florida Health/Wellness Fair, "Allergic Rhinitis and Respiratory Illness", October 27, 2004.

30. Course Director, Symposium - Update in Allergy and Immunology, sponsored by USF Health, University of South Florida, Orlando, FL, September 26 – 27, 2008. Lecture presented in absence of Richard F. Lockey MD by Dennis Ledford, MD, September 27, 2008, "Evaluation and Management of Chronic Sinusitis".

31. Symposium - Advances in Chronic Infections and Inflammatory Diseases. Sponsored by Signature Interdisciplinary Program in Allergy, Immunology and Infectious Disease (SIPAIID), University of South Florida College of Medicine, Tampa, FL, January 29 – 30, 2009.
    a) Chair, "Cellular and Molecular Basis Airway Inflammation"
    b) Chair, "Neurogenic Inflammation and RSV"

32. Course Director, Symposium - Update in Allergy and Immunology, sponsored by USF Health, University of South Florida, Westin Harbour Island, Tampa, FL, September 25, 2010.
    Speaker, "Asthma and its Comorbities.

33. Speaker, University Community Hospital for the Department of Pediatrics, University of South Florida College of Medicine, Tampa, Florida, November 10, 2010, "Asthma and Comorbid Conditions in Children".

34. Course Director, Symposium - Update in Allergy and Immunology, sponsored by USF Health, University of South Florida, Westin Harbour Island, Tampa, FL, October 1, 2011.
    Speaker, "Phenotypes of Asthma and their Comorbities".

35. Course Director, Symposium - Update in Allergy and Immunology, sponsored by USF Health, University of South Florida, Center for Advanced Medical Learning and Simulation (CAMLS), Tampa, FL, October 5 - 6, 2012.

36. OB/GYN Grand Rounds, USF Morsani College of Medicine, Tampa, FL, September 4, 2013.

37. Surgery Grand Rounds, USF Morsani College of Medicine, Tampa, FL, September 9, 2013, "Diagnosing and Treating Anaphylaxis".

38. Course Director, 2013 Symposium & Rhinolaryngoscopy Hands-On Workshop – Update in Allergy and Immunology, sponsored by USF Health, University of South Florida, Center for Advanced Medical Learning and Simulation (CAMLS), Tampa, FL, September 27 - 28, 2013.

39. Department of Internal Medicine, Roy H. Behnke, MD Grand Rounds Lecture Series, USF Morsani College of Medicine, Tampa, FL, October 31, 2013, "A Focus on Angioedema".

40. Department of Internal Medicine, Roy H. Behnke, MD Grand Rounds Lecture Series, USF Morsani College of Medicine, Tampa, FL, August 7, 2014, "Anaphylaxis".

41. Course Director, 2014 Symposium & Hands-On Rhinolaryngoscopy Workshop – Update in Allergy and Immunology, sponsored by USF Health, University of South Florida, Center for Advanced Medical Learning and Simulation (CAMLS), Tampa, FL, October 17 - 18, 2014.
    Speaker: 1) Sublingual Immunotherapy
    2) Asthma: Co-morbid and Co-Existing Conditions

42. Speaker, Tampa General Noon Conference, Tampa, FL, October 22, 2014, "Rhinitis".

43. Speaker, Tampa General Noon Conference, Tampa, FL, November 12, 2015, "Asthma".

44. Course Director, Symposium - Update in Allergy and Immunology, sponsored by USF Health, University of South Florida, Center for Advanced Medical Learning and Simulation (CAMLS), University of South Florida, Tampa, FL, December 11 - 12, 2015. Speaker, "Indoor Allergens".

45. Department of Internal Medicine Roy H. Behnke Internal Medicine Grand Rounds, USF Morsani College of Medicine, Tampa, FL, May 5, 2016, "Asthma, Phenotypes, Differential Diagnosis and Comorbid Conditions".

46. Speaker, Section of Surgery, James A. Haley Veterans' Administration Hospital, July 28, 2016, "Understanding, recognizing and treating anaphylaxis".

47. Speaker, OB/GYN Grand Rounds, USF Morsani College of Medicine, Department of Obstetrics & Gynecology, September 7, 2016, "Understanding, Recognizing and Treating Anaphylaxis".

47. Speaker, noon conference, Department of Pediatrics, Division of Allergy and Immunology; Tampa General Hospital, September 15, 2016, "Anaphylaxis".

49. Speaker, USF Internal Medicine Lecture Series, September 21, 2016, "Asthma".

49. Speaker, noon conference, Department of Pediatrics, Division of Allergy and Immunology; Tampa General Hospital, September 29, 2016, "Assessing the Role of Comorbid Conditions as an Integral Part of Asthma Management".

50. Course Director, Symposium - Update in Allergy and Immunology, sponsored by USF Health, University of South Florida, Center for Advanced Medical Learning and Simulation (CAMLS), University of South Florida, Tampa, FL, October 21 – 22, 2016. Speaker, "Comorbid Conditions of Asthma and COPD", and "History and Evolution of Allergen Immunotherapy".

51. Keynote speaker, 7th Annual Scholarly Concentration Symposium, USF Morsani College of Medicine, November 4, 2016, "My 50 Years of Fun, Caring for Patients, Teaching and Research Continues".

52. Speaker, Grand Rounds, Student Health Services and USF Health, July 19, 2017, "Guidelines for Asthma Treatment".

53. Speaker, Tampa General Hospital Noon Conference, Department of Pediatrics, Division of Allergy and Immunology, October 18, 2017, "Asthma".

54. Speaker, Department of Pediatrics, University of South Florida College of Medicine, January 18, 2018, "Asthma".

55. Course Director, 2018 Symposium - Update in Allergy and Immunology, sponsored by USF Health, University of South Florida, Center for Advanced Medical Learning and Simulation (CAMLS), University of South Florida, Tampa, FL, January 19 - 20, 2018. Speaker, "Evaluation of and Testing for Beta Lactam Allergy", and "When is Epinephrine indicated for a Food Induced Systemic Allergic Reaction".

56. Plenary Speaker, USF Marshall Student Center, March 22, 2018, "Reflections of my Journey as an Eagle Scout".

57. Speaker, Tampa General Hospital Lecture Series, Department of Internal Medicine, Division of Allergy and Immunology, August 15, 2018, “Anaphylaxis”.

58. Course Director, 2020 Symposium - Update in Allergy and Immunology, sponsored by USF Health, University of South Florida, Center for Advanced Medical Learning and Simulation (CAMLS), University of South Florida, Tampa, FL, January 17 - 18, 2020. Speaker, “Severe Asthma: With or Without Monoclonals? (PBL)”, and “Temporomandibular Joint (TMJ) Dysfunction and Headaches, Case Presentation and Discussion”.

RESEARCH STUDIES:

USF CRU COMPREHENSIVE STUDY LIST

Title	PI	Date	Status	Sponsor	Funds	IRB #
[protocol no. SARCA] The Study of Acid Reflux in Children with Asthma (SARCA)	Lockey	2009	Closed - PI	American Lung Association		**105583**
[protocol no. APR] Asthma Patient Registry	Lockey	09/14/2009	Approved, Open	American Lung Association		**108273**
Repeated Nasal Challenge in Skin Prick-Puncture Negative, Intradermal Positive Dust Mite Allergic Rhinitis Patients	Lockey	01/03/2008	Approved, Open	Division Sponsored		**106217**
[protocol no. SOYA] The Study of Soy Isoflavones in Asthma	Lockey	2010	Approved, Open	American Lung Association		**Pro00000006**
[protocol no. STAN] Study of Asthma and Nasal Steroids	Lockey	10/26/2009	Approved, Open	American Lung Association		**Pro00000009**
[protocol no. LASST] Long Acting Beta Agonist Stepdown Study (LASST)	Lockey		Pending	American Lung Association		**Pro00007478**
Calcium Intake in Children on Inhaled or Intranasal Corticosteroids	Lockey	Submission review in progress	Pending	Division Sponsored		**Pro00006255**
Obesity & Asthma: Genetics and Nutrigenetic Response to Omega-3 Fatty Acids	Lockey	01/10/2012	Approved, Open	National Institute of Health		**Pro00006491**
Effect of Oxymetazoline Hydrochloride in Combination with Nasal Glucocorticoid on the Apnea Hypopnea Index (AHI), nocturnal oxyhemoglobin saturation, snoring, and sleep quality in Subjects with Persistent Nasal Congestion.	Lockey	05/23/2011	Approved, Open	Division Sponsored		**Pro00001844**

Identification of Plasma miRNAs as Potential Biomarkers in Asthma exacerbation	Lockey	08/09/2011	Approved, Open	Division Sponsored		**Pro00005011**
Myeloid Suppressors in Inflammation	Lockey	9/18/2012	Closed-PI	Division Sponsored		**Pro00001787**
Procalcitonin Level as a Diagnostic Aid in Acute Bacterial Sinusitis	Lockey	4/2/2012	Closed - PI	Division Sponsored		**106936**
[protocol no. PO4230] A Randomized, 26-Week, Placebo-Controlled Efficacy and Safety Study with a 26-week Long Term Safety Extension, of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared with Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects with Moderate to Severe COPD	Lockey	11/17/2011	Closed - PI	Schering-Plough Corporation		**105348**
[protocol no. XRG5029C/3503] A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study of the 12 Month Effect of Treatment with Once Daily Triamcinolone Acetonide (NASACORT® AQ Nasal Spray 110 ug) on the Growth Velocity of Children, 3 to 9 Years of Age, with Perennial Allergic Rhinitis (PAR)	Lockey	10/13/2011	Closed - PI	Sanofi-Aventis		**105347**
Oxymetazoline Hydrochloride in Combination with Nasal Glucocorticosteroid for Perennial Allergic and Non-Allergic Rhinitis in Subjects with Persistent Nasal Congestion	Lockey	2/1/2011	Closed - PI	Division Sponsored		**102621**

[protocol no. D5896C00022] A 52-Week, Randomised, Double-Blind, Parallel-Group, Multi-Centre, Phase IIIB Study Comparing the Long Term Safety of SYMBICORT pMDI 160/4.5 ug x 2 Actuations Twice Daily to Budesonide HFA pMDI 160 ug x 2 Actuations Twice Daily in Adult and Adolescent (>- 12 Years) African American Subjects with Asthma	Lockey	1/12/2011	Closed - PI	AstraZeneca Ltd.		**105669**
[protocol no. MK 0476-377] A Double-Blind, Placebo-Controlled, Multicenter, Crossover Study to Evaluate the Effects of a Single Oral Dose of Montelukast, Compared with Placebo, on Exercise-Induced Bronchoconstriction (EIB) in Pediatric Patients Aged 4 to 14 Years	Lockey	12/15/2010	Closed - PI	Merck & Company, Inc.		**107559**
Effect of Supplemental Oral Curcumin in Patients with Atopic Asthma	Lockey	10/20/2010	Closed - PI	Division Sponsored		**107393**
Interleukin-13 in Chitin Allergic, Steroid Non-Responsive Moderate to Severe Asthmatics	Lockey	10/20/2010	Closed - PI	Division Sponsored		**108406**
[protocol no. PGX003] A Phase I, Randomized Crossover, Double-Blind, Placebo-Controlled Pilot Study Evaluating the Safety of Apadenoson Use in Subjects with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)	Lockey	7/5/2010	Closed - PI	PGxHealth, LLC		**108074**
[protocol no. PGX002] A Phase I, Randomized Crossover, Double-Blind, Placebo-Controlled Pilot Study Evaluating the Safety of Apadenoson Use in Subjects with Mild to Moderate Asthma	Lockey	7/5/2010	Closed - PI	PGxHealth, LLC		**108083**
[protocol no. MeCIS] Methacholine Bronchoprovocation - Influence of High Potency Inhaled	Lockey	6/8/2010	Closed - PI	American Lung Association		**107044**

Corticosteroids in Asthma (MeCIS)						
[protocol no. QAB149B2349] A 12 Week Treatment, Multi-Center, Randomized, Parallel Group, Double Blind, Double Dummy Study to Assess the Superiority of Indacaterol (150 ug o.d.) via a SDDPI in Patients with Moderate to Severe COPD, using Salmeterol (50 ug b.i.d.) as an Active Comparator Delivered via a DISKUS Inhaler	Lockey	1/19/2010	Closed - PI	Novartis Pharmaceutical Corporation		**107560**
[protocol no. MK-0633-007] A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group, Dose-Ranging Study of MK-0633 in Adult Patients with Chronic Asthma	Lockey	1/4/2010	Closed - PI	Merck & Company, Inc.		**106358**
[protocol no. MK-0633-009] A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions of MD-0633 in Patients with COPD	Lockey	11/30/2009	Closed - PI	Merck & Company, Inc.		**106370**
[protocol no. ADC111891] An Evaluation of Lung Function and Symptoms in Patients with Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy	Lockey	11/7/2009	Closed - PI	GlaxoSmithKline		**107394**
Naturalistic Studies of Parental Permission and Assent for Research	Lockey	10/27/2009	Closed - PI	Nemours Foundation		**107349**
[protocol no. MK-0633-007 Extension] A Double-Blind, Placebo-Controlled Extension to the Study of MK-0633 in Adult Patients with Chronic Asthma (Extension to Protocol 007)	Lockey	10/20/2009	Closed - PI	Merck & Company, Inc.		**107287**

[protocol no. CQAB149B2335S] A 26-Week Treatment, Multicenter, Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Adaptive, Seamless, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (Selected from 75, 150, 300 & 600 ug o.d.) in Patients with Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 ug b.i.d.) and Open Label Tiotropium (18 ug o.d.) as Active Controls CQAB149B2335S	Lockey	5/4/2009	Closed - PI	Novartis Foundation		**105704**
[protocol no. PO4705] A 52-Week Efficacy and Safety Non-Interiority Study of Fluticasone Propionate/Salmeterol 250/50 mcg BID Delivered by Dry Powder Inhaler (Diskus) Versus Mometasone Furoate/Formoterol Fumerate 200/10 mcg BID Delivered by Pressurized Metered-Dose Inhaler in Persistent Asthmatics Previously Treated with Medium Doses of Inhaled Glucocorticosteroids PO4705	Lockey	4/27/2009	Closed - PI	Schering-Plough Corporation		**105722**
Topical Antibiotic Use in Chronic Rhinosinusitis, a Double-Blinded, Randomized, Placebo Controlled Study	Lockey	4/27/2009	Closed - Expired	USF Asthma, Allergy & Immunology		**106811**
Altana Pharma [protocol no. BY217/M2-124] Effect of roflumilast on exacerbation rate in patients with COPD. A 52-week, double-blind study with 500 mcg roflumilast once daily versus placebo	Lockey	3/10/2009	Closed - PI	Altana Pharma		**104723**
[protocol no. ADA109057] A 52-Week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg	Lockey	3/2/2009	Closed - PI	Glaxo SmithKline		**105618**

BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma						
[protocol no. SKY2028-3-004] A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Stratified, Multi-Center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm 100/10ug or 250/10ug twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Placebo or Fluticasone (250ug twice daily) and Formoterol (10ug twice daily) Alone in Adolescent and Adult Patients with Moderate to Severe Asthma	Lockey	11/24/2008	Closed - PI	Skye Pharma, Inc.		**105273**
Association of Atrial Natriuretic Peptide Gene Polymorphism and Asthma Severity	Lockey	9/22/2008	Closed - PI	Division Sponsored		**105901**
[protocol no. M05-757] A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects with Refractory Asthma, Protocol M05-757	Lockey	9/8/2008	Closed - PI	Abbott Laboratories		**106070**
Predicting the Diagnosis of Asthma Based on History	Lockey	6/30/2008	Closed - PI	Division Sponsored		**104847**

[protocol no. CIGE025AUS23] A 26-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of Xolair (omalizumab) on A 26-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of Xolair (omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients with at Least Moderate Persistent Allergic Asthma Inadequately Controlled with Inhaled Corticosteroids - CIGE025AUS23	Lockey	3/3/2008	Closed - PI	Novartis Pharmaceutical Corporation		**104336**
The Use of Topical Antibiotics in Chronic Rhinosinusitis	Lockey	2/25/2008	Closed - Expired	Division Sponsored		**104174**
[protocol no. OPL104226] A Prospective Observational Study for the Psychometric Validation of a Patient-Reported Questionnaire in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) - OPL104226	Lockey	1/2/2007	Closed - PI	GlaxoSmithKline		**104175**
[protocol no. SLIT03-04] Safety and Dosing Study for Sublingual-Oral Administration of Standardized Glycerinated Cat Hair Allergenic Extract - SLIT03-04	Lockey	12/28/2006	Closed - PI	Greer Laboratories, Inc.		**103315**
[protocol no. SB207499, CIL103657] A Randomized, 24-week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD)	Lockey	11/27/2006	Closed - PI	GlaxoSmithKline		**103129**
[protocol no. SIRNA] Sinusitis and Rhinitis in Asthma (SIRNA)	Lockey	11/14/2006	Closed - PI	American Lung Association		**104152**

[protocol no. SFA 100062] A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at Least 12 Years of Age, with Persistent Asthma, Who Have Either a B16-Arg/Arg, a B16-Gly/Gly or a B-16 Arg/Gly Genotype and are Treated with Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg or Salmeterol DISKUS 50 mcg BID - SFA100062	Lockey	11/6/2006	Closed - PI	GlaxoSmithKline		**103081**
Determination of a Specific Phenotype for Asthma and Allergy	Lockey	11/6/2006	Closed - PI	Division Sponsored		**4573**
[ALA protocol no. TAPE] Effect of Education and Drug Presentation on Efficacy of Montelukast and Placebo in Asthma (TAPE)	Lockey	11/2/2006	Closed - PI	National Institutes of Health/DHHS		**101072**
[protocol no. DX-88/5 EDEMA 2] An Open Label Study to Assess the Efficacy and Tolerability of Repeated Doses of DX-88 (recombinant plasma kallikrein inhibitor) in Patients with Hereditary Angioedema - DX-88/5	Lockey	9/25/2006	Closed - PI	Dyax Corp.		**101852**
[protocol no. SCO40043] A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50mcg BID with Salmeterol DISKUS 50 mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	Lockey	9/11/2006	Closed - PI	GlaxoSmithKline		**102880**
Impact of an Asthma Camp on Knowledge and Clinical Outcomes	Lockey	6/22/2006	Closed - PI	Division Sponsored		**103753**

[protocol no. DX-88/4] **An Ascending Four Dose Placebo Controlled Study to Assess the Efficacy and Tolerability of DX-88 (Recombinant Plasma Kallikrein Inhibitor) Administered Following Onset of Acute Attacks of Hereditary Angioedema**	Lockey	2/21/2005	Closed - PI	Dyax Corp.		**100778**
Effect of Aging and the Effect of Sun Damage on Allergy Skin Tests	Lockey	2/15/2005	Closed - PI	Division Sponsored		**5091**
A Multi-Center, Multinational, Randomized, Double-Blind, Parallel Group Study of the Effects of Ciclesonide HFA-MDI 640 uG/Day and Beclomethasone HFA-MDI 640 uG/Day on Lens Opacification In Adult Subjects with Moderate to Severe Persistent Asthma	Lockey	1/31/2005	Closed - PI	Aventis Pharmaceuticals		**102142**
[protocol no. SAM 40065] **A Multi-Center, Randomized, Double-Blind, Parallel group, 40-Week Comparison of Asthma Control Using Bronchial Hyperresponsiveness As An Additional Guide to Long-Term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol Diskus Bid or Fluticasone Propionate Diskus Bid (or Placebo Bid if Asymptomatic)**	Lockey	1/24/2005	Closed - PI	GlaxoSmithKline		**101171**
[protocol no. 197-01-210] **A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Dose Comparison study of the Efficacy and Safety of Oral 25mg, 50mg, 75mg OPC-6535 and Placebo in the Treatment of Patients with Chronic Obstructive Pulmonary Disease**	Lockey	1/11/2005	Closed - PI	Otsuka America Pharmaceutical, Inc.		**100034**

[protocol no. ONO-6126POU011] A Four Week, Double Blind, Placebo-Controlled, Exploratory Evaluation of Fev 1.0 Changes and Safety of ONO-6126 in Patients with Chronic, Obstructive Pulmonary Disease (COPD)	Lockey	12/14/2004	Closed - PI	Ono Pharma USA		**101986**
[protocol no. ANC-MD-17] Double Blind Study of the Efficacy, Safety, and Pharmacoeconomics of Flunisolide HFA Inhaler System as Compared to Fluticasone Inhalation Aerosol in Patients with Asthma	Lockey	11/1/2004	Closed - PI	Forest Lab.		**100855**
[protocol no. Q2196N] An Observational Study of the Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (Tenor)	Lockey	9/2/2004	Closed - PI	Genentech, Inc.		**6063**
Parietaria Floridana and Allergic Rhinitis in the Tampa Bay Area	Lockey	3/9/2004	Closed - PI	Division Sponsored		**5786**
International Study of Asthma and Allergies in Childhood (ISAAC), Data from the West Coast of Florida	Lockey	2/24/2004	Closed - PI	Asthma & Allergy Foundation of America (Florida)		**101098d**
[protocol no. MO16455P/3001] A Multicenter, Double-Blind, Randomized, Parallel Groups, Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120 MG BID in Subjects with Mild to Moderate Persistent Asthma	Lockey	1/31/2004	Closed - PI	Aventis		**100033**
[protocol no. M016455P-3003] A Multicenter, Open-Label, Randomized, Parallel Groups Study to Assess the Long-Term Safety Performance of Fexofenadine Compared to Montelukast in Subjects with Asthma	Lockey	1/31/2004	Closed - PI	Aventis		**100032d**

[protocol no. 340-72] **Efficacy and Safety of Monetasone Furoate Dry Powder Inhaler in the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)**	Lockey	1/31/2004	Closed - PI	Schering-Plough Corporation		**5787**
[protocol no. SAS 30028] **A Stratified, Randomized, Double-Blind, Parallel-Group, Multi-Center, 96-Week Study Evaluating the Growth Effects of Fluticasone Propionate/Saimeterol DISKUS Combination Product 100/50mcg Twice Daily versus Usual Non-Corticosteriod Maintenance Therapy in Pre-Pubescent Pediatric Subjects with Asthma**	Lockey	1/26/2004	Closed - PI	GlaxoSmithKline		**101073**
[protocol no. Merck 016-00] **A Double-Blind, Randoimized, Placebo-Controlled, Multicenter, Parallel-Group, Proof-of-Concept Study of L-000454560 in Patients With COPD**	Lockey	12/31/2003	Closed - PI	Merck & Company, Inc.		**101086c**
12 Weeks Treatment with 250ug Roflumilast versus Placebo in Patients with Asthma	Lockey	10/31/2003	Closed - PI	Altana, Inc.		**6529d**
Possible Allerginicity of Oak Acorns	Lockey	10/31/2003	Closed - PI	Division Sponsored		**6518d**
[protocol no. SAS40037] **A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group, 16-Week Comparison of Asthma Control in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS® Combination Product 100/50mcg BID, Fluticasone Propionate DISKUS® 100mcg BID, Salmeterol Xinafoate DISKUS® 50mcg BID, or Oral Motelukast 100mg QD**	Lockey	8/31/2003	Closed - PI	GlaxoSmithKline		**6465c**

[protocol no. SAM40066] **A Multi-Center, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving Concurrent Open-Label ADVAIR DISKUS 100/50mcg BID**	Lockey	8/31/2003	Closed - PI	GlaxoSmithKline		**100577d**
[protocol no. P01861] **A Placebo- and Active-Controlled Efficacy and Safety Study of a Once-Daily Fixed Combination Tablet of Desloratadine 5mg / Pseudoephedrine 120mg (SCH 483 [5/120]) in Subjects With Seasonal Allergic Rhinitis**	Lockey	8/31/2003	Closed - PI	Schering-Plough Corporation		**100611d**
[protocol no. FAP 30010] **A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88MCG BID Versus Placebo in Propellant GR106642X in Pediatric Subjects 4 to 11 Years of Age with Asthma**	Lockey	8/31/2003	Closed - PI	GlaxoSmithKline		**6459**
[protocol no. M016455M/3002 (PAR)] **A Multicenter, Double-Blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Fexofenadine 120 mg BID, Fexofenadine 240 mg QD, and Placebo in Subjects with Perennial Allergic Rhinitis**	Lockey	7/31/2003	Closed - PI	Aventis		**100544**
[protocol no. LODO] **Effectiveness of Low-Dose Theophylline as Add-On Therapy in the Treatment of Asthma ("The LoDo Trial")**	Lockey	7/31/2003	Closed - PI	American Lung Association		**6356d**

[protocol no. SD004-0111] START-Inhaled Steroid Treatment As Regular Therapy in Early Asthma: A Study of the Effect of Early Intervention With Long-Term Inhaled Budesonide (Pulmicort(R) Turbuhaler(R)) in Newly Diagnosed Asthma	Lockey	5/31/2003	Closed - PI	AstraZeneca Ltd.		**4362**
[protocol no. 309801] A Phase 3 Study to Determine the Efficacy and Safety of C1-Inhibitor (Human) Vapor Heated, Immuno in Subjects with Hereditary Angioedema (HAE)	Lockey	4/30/2003	Closed - PI	Baxter Healthcare Corporation		**5812**
[protocol no. 07] A Double Blind, Placebo Controlled, Long Term Growth Study of HFA Flunisolide in Children with Mild Asthma	Lockey	12/31/2002	Closed - PI	Forest Laboratories, Inc.		**5707**
[protocol no. ANC-MD-09] Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Once Daily Flunisolide HFA Inhaler System in Patients with Asthma Currently Treated with Inhaled Steroids	Lockey	12/31/2002	Closed - PI	Forest Laboratories, Inc.		**6103**
[protocol no. SAVE] URTI Symptom Score Pilot Study	Lockey	12/31/2002	Closed - PI	American Lung Association		**6603**
[protocol no. PO1978] Placebo Controlled Efficacy and Safety Study of a Once-Daily PM and Twice Daily Regimens of Mometasone Furoate Administered Via Dry Powder Inhaler in Subjects with Asthma Who Were Previously Maintained on Inhaled Corticosteroids	Lockey	10/31/2002	Closed - PI	Schering-Plough Corporation		**6050**
[protocol no. 051-915] A Randomized, Double-Blind Study to Determine the Efficacy of Levalbuterol Versus Racemic Albuterol in the	Lockey	9/30/2002	Closed - PI	Sepracor, Inc.		**5969**

Treatment of Acute Asthma						
A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 8 Week Comparison of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate Plus Ipratropium Bromide Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease	Lockey	8/31/2002	Closed - PI	Glaxo Wellcome, Inc.		**5944**
[protocol no. SMS40321] A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group comparison of Salmeterol Xinafoate Inhalation Aerosol Versus Ipratropium Bromide and Albuterol Sulfate Inhalation Aerosol in Subjects With Chronic Obstructive Pulmonary Disease	Lockey	8/31/2002	Closed - PI	GlaxoSmithKline		**6424**
[protocol no. M016455A/4122] A Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Randomized Study of Fexofenadine HCL 180 MG vs. Cetirizine HCL 10 MG in Subjects with Moderate to Severe Seasonal Allergic Rhinitis (SAR) During the Fall or Winter/Spring Allergy Season	Lockey	7/31/2002	Closed - PI	Aventis		**6379**
A Randomized, Double-Blind, Double Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50 mdg BID) via DISKUS® with Oral Montelukast (5 mg QD) Chewable Tablets in Children 6 to 12 Years of Age with Persistent Asthma	Lockey	7/31/2002	Closed - PI	Glaxo Wellcome, Inc.		**5921**

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Virologic Activity, and Safety of Pleconaril (Oral Suspension) in the Treatment of Viral Respiratory Infection in Children 1 to 6 Years of Age	Lockey	7/31/2002	Closed - PI	ViroPharma, Inc.		**6388**
[protocol no. 061/059] **A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Virologic Activity, and Safety of Pleconaril (Oral Suspension) in the Treatment of Viral Respiratory Infection in Children 7 to 12 Years of Age**	Lockey	7/31/2002	Closed - PI	ViroPharma, Inc.		**6389**
[protocol no. SIIVA] **A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of the Safety of Inactivated Influenza Vaccine in Adults and Children with Asthma**	Lockey	6/30/2002	Closed - PI	American Lung Association		**5853**
Qualitative Interview Regarding Experiences on Bayer 19-8004 Trial	Lockey	5/31/2002	Closed - PI	Bayer Corporation		**6290**
The Efficacy of Disodium Octaborate Tetrahydrate (DOT) and Vacuum Cleaning in Lowering House Dust Mite Population and House Dust Mite Allergen Levels in Homes	Lockey	5/31/2002	Closed - PI	Division Sponsored		**5841**
[protocol no. M97700-023] **A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Dose-Finding Study to Evaluate the Effectiveness of 28 Days of Treatment with LDP-977 in Adult Asthmatics**	Lockey	4/30/2002	Closed - PI	Millenium Pharmaceuticals, Inc.		**6252**
Rhinitis in Patients with Gastroesophageal Reflux: Prevalence and Characterization	Lockey	4/30/2002	Closed - PI	Division Sponsored		**5664**

A Twelve Month, Open Label Study of Oxis™ Turbuhaler® in Adults and Adolescents with Asthma	Lockey	1/31/2002	Closed - PI	AstraZeneca Ltd.		**6110**
[protocol no. ADVIL SAR-AD-99-02] Advil Multi-Symptom Allergy Sinus Efficacy and Safety Study	Lockey	1/31/2002	Closed - PI	Whitehall-Robins Healthcare		**6111**
A Randomized, Double-Blind, Multicenter Study to Evaluate the Effect of Adding Either Montelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics	Lockey	9/30/2001	Closed - PI	Merck & Company, Inc.		**5561**
A Phase III, Multicenter, Double-Blind, Parallel Group Study Assessing the Effects of Triamcinolone Acetonide HFA-134A MDI on Growth in Asthmatic Children	Lockey	8/31/2001	Closed - PI	Aventis		**5486**
[protocol no. C98-477] Double-Blind Study of the Effects of One Year of Treatment with Mometasone Furoate HFA-227 Metered Dose Inhaler (MF MDI) vs. Placebo on Growth of Children with Asthma	Lockey	8/31/2001	Closed - PI	Schering-Plough Corporation		**5190**
A Multicenter, Randomized, Double-Blind Pilot Study Comparing the Clinical Effect of Intravenous Montelukast with Placebo in Patients with Acute Asthma	Lockey	4/30/2001	Closed - PI	Merck & Company, Inc.		**5750**
Melaleuca Tree and Respiratory Disease	Lockey	4/30/2001	Closed - PI	Division Sponsored		**5808**
[protocol no. BAY 19-8004] A Randomized, Double-Blind, Parallel Group Comparison of the Safety and Efficacy of Three Once Daily Doses of BAY 19-8004 with Placebo and Montelukast 10mg Daily in Patients with Symptomatic Asthma	Lockey	3/31/2001	Closed - PI	Bayer Corporation		**5732**

[protocol no. 155] 1999 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Determine the Efficacy of Oral Zafirlukast (ACCOLATE-TM) When Administered According to Current Labeling Instructions or Simplified Dosing Instructions in Subjects with Asthma Receiving Inhaled B2-Agonist Alone or Inhaled B2-Agonist in Combination with Inhaled Corticosteroids (ICS)	Lockey	3/31/2001	Closed - PI	AstraZeneca Ltd.		**5322**
Allergy to Ferret	Lockey	2/28/2001	Closed - PI	Division Sponsored		**5562**
[protocol no. MK-013-00] A Double-Blind, Randomized, Placebo- and Active-Controlled, Multicenter, Parrallel-Group, Dose-Ranging Study of L753099 in Patients with COPD	Lockey	1/31/2001	Closed - PI	Merck & Company, Inc.		
[protocol no. 0476-074-00 Extension] A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Crossover Study Comparing Combination Montelukast/Loratadine With Montelukast and Loratadine Monotherapies in Patients With Chronic Asthma	Lockey	1/31/2001	Closed - PI	Merck & Company, Inc.		**5528**
[protocol no. P00355-18] Efficacy and Safety of SCH 34117 + Pseudoephedrine, BID, vs. its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis	Lockey	9/30/2000	Closed - PI	Schering-Plough Corporation		**5475**
Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler (MF-MDI) in the Treatment of Asthma in Children Previously Maintained on Anti-Inflammatory Asthma Medications	Lockey	9/30/2000	Closed - PI	Schering-Plough Corporation		**5173**

[protocol no. FLTA 4039] A Randomized, Double-Blind, Parallel Group Comparison Study of Inhaled Fluticasone Propionate (88mcg bid) Versus Montelukast Sodium (10 mg QD) in Subjects Currently Receiving Beta Agonists Alone	Lockey	8/31/2000	Closed - PI	Glaxo Wellcome, Inc.		**5145**
[protocol no. SFCA 3006] 1998 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol 50mcg BID and Fluticasone Propionate 500mcg BID Individually and in Combination as Compared to Placebo in COPD Subjects	Lockey	7/31/2000	Closed - PI	Glaxo Wellcome, Inc.		**5146**
Biological Standardization: The Quantatative Skin Response in Subjects Skin Tested with Varying Doses of Skin Reactive Substances	Lockey	7/31/2000	Closed - PI	National Institutes of Health/DHHS		**5108**
[protocol no. P00221] Efficacy and Safety in the Treatment of Chronic Idiopathic Urticaria (CIU) Subjects with SCH 34117	Lockey	5/31/2000	Closed - PI	Schering-Plough Corporation		**5375**
[protocol no. 253-102] Phase IIA Multicenter, Randomized, Double-Blind, Double-Dummy, Active and Placebo-Controlled, Parallel Group, Dose-Response Study of the Efficacy, Safety, and Tolerability of Six Weeks Oral Dosing with CJ-13,610 Compared to Montelukast and Placebo in Adults with Persistent Asthma	Lockey	5/31/2000	Closed - PI	Pfizer, Inc.		**5372**
[protocol no. ANC-MD-04-000] A One-Year, Open-Label Study to Evaluate the Safety of HFA Flunisolide in Children with Mild to Moderate Asthma	Lockey	4/30/2000	Closed - PI	Forest Laboratories, Inc.		**5042**

A Multicenter, Double-Blind, Randomized Study Comparing a Combination Tablet Containing Montelukast + Loratadine with Inhaled Beclomethasone in Patients with Chronic Asthma	Lockey	3/31/2000	Closed - PI	Merck & Company, Inc.		**5025**
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of Salmeterol/Fluticasone Propionate Combination in GR106642X MDI, 50/250mcg BID, and Salmeterol in Propellant 11/12 MDI, 50mcg BID, Fluticasone Propionate in Propellant 11/12 MDI, 250mcg BID, and Placebo in Propellant GR106642X MDI in Adolescent and Adult Subjects with Asthma	Lockey	3/31/2000	Closed - PI	Glaxo, Inc.		**5339**
[protocol NKP608] A Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled, Dose-Ranging Trial to Assess the Efficacy and Safety of NKP 608 Microemulsion Capsules in Adult Patients with Chronic Bronchitis	Lockey	10/31/1999	Closed - PI	Novartis Pharmaceutical Corporation		**5169**
[protocol no. Formoterol 056) Randomized, Double-Blind, Between-Patient Trial Comparing Two Doses of Inhaled Formoterol Fumarate Dry Powder (12 and 24 ug b.i.d.) with Placebo and Ipratropium Bromide MDI (40 ug q.i.d.) for 12 Weeks in Patients with Chronic Obstructive Pulmonary Disease, in Terms of Clinical Efficacy, Tolerability and Quality of Life	Lockey	9/30/1999	Closed - PI	Novartis Pharmaceutical Corporation		**5152**

A Comparison of the Effect of Two Doses of Levalbuterol with Ventolin on Pulmonary Function in Subjects with Mild to Moderate Asthma	Lockey	6/30/1999	Closed - PI	Sepracor, Inc.		**5084**
A Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects with Co-Morbid Asthma and a History of Seasonal Exacerbations of Asthma on Medical Resources Utilization (for Asthma and SAR)	Lockey	5/4/1999	Closed - PI	Integrated Therapeutics Group, Incorporated		**4962**
[protocol no. L808, 065-011 #004] A Multicenter, Double-Blind, Placebo-Controlled Study Comparing the Clinical Effect of Nebulized L-808,065 in Patients with Chronic Asthma	Lockey	4/21/1999	Closed - PI	Merck & Company, Inc.		**5170**
Understanding of Asthma Through Educational Intervention	Lockey	4/21/1999	Closed - PI	Integrated Therapeutics Group, Incorporated		**4534**
[protocol no. RG5016T 310, Azmacort HFA Study 204] A Phase II/III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of Azmacort(R) (triamcinolone acetonide) HFA-134a Inhalation Aerosol 225 mcg, 460 mcg and 900 mcg Administered Once Daily for 12 Weeks in the Treatment of Mild Persistent and Moderate Persistent Asthma in 800 Adolescents and Adults	Lockey	3/3/1999	Closed - PI	Rhone-Poulenc Rorer Central Pharmaceuticals		**4801**
A Randomized, Open Label, Cross-Over Study Comparing the Parent/Guardian Preference for Montelukast Sodium Tablets or Cromolyn Sodium Aerosol (MDI) Treatment in their Children Ages	Lockey	3/3/1999	Closed - PI	Merck & Company, Inc.		**4437**

6 to 11 with Chronic Asthma						
Quantitative Intradermal Test Procedure to Evaluate Subject Sensitivity to Euroglyphus Maynei and Blomia Tropicalis House Dust Mites and to Determine the Biological Potency of Euroglyphus Maynei and Blomia Tropicalis Using the ID50EAL Method - A Single Center Trial	Lockey	2/28/1999	Closed - PI	Bayer Corporation		**4032**
Safety Evaluation of Once Daily Dosing of Fexofenadine HCl 180 mg in Subjects with Seasonal Allergic Rhinitis and Concomitant Mild to Moderate Asthma	Lockey	2/4/1999	Closed - PI	Hoechst-Marion Roussel, Inc.		**5076**
A comparative Study of the Efficacy and Safety of Clarithromycin Immediate Release Tablets and Loracarbef Pulvules for the Treatment of Patients with Secondary Bacterial Infection of Acute Bronchitis	Lockey	11/4/1998	Closed - PI	Abbott Laboratories		**5106**
A Repeat-Dose, Dose-Ranging, Placebo-Controlled, Study of the Safety and Efficacy of SB 210396 in Patients with Chronic Severe Asthma	Lockey	10/21/1998	Closed - PI	Smithkline Beecham		**4301**
[protocol no. MK0476-031-20, extension] An Open, Controlled Extension to the MK-0476 versus Placebo Comparison Study to Investigate the Long-Term Safety and Tolerability of MK-0476 in Patients with Chronic Asthma	Lockey	10/21/1998	Closed - PI	Merck & Company, Inc.		**3633**
[protocol no. Accolate 9188IL-095 extension] A Multicenter, Randomized, Double-Blind Placebo Controlled Trial of Zafirlukast (Accolate) in Subjects With Mild to Moderate Asthma: 3 Weeks	Lockey	9/15/1998	Closed - PI	Zeneca Pharmaceutical Group		**3959**

Efficacy and Up to 52 Weeks Open-Label Safety Extension						
Aerobid-Once-A-Day with AeroChamber in Mild to Moderate Asthma Patients	Lockey	9/15/1998	Closed - PI	Forest Laboratories, Inc.		**4752**
[protocol no. SLGA 4020] 1997 A Comparison of Salmeterol vs. Theophylline vs. Salmeterol Plus Theophylline in COPD Patients (GlaxoWellcome)	Lockey	8/4/1998	Closed - PI	Glaxo Wellcome, Inc.		**4536**
Treatment of Post-Viral Cough with Beclomethasone	Lockey	6/30/1998	Closed - PI	Glaxo Wellcome, Inc.		**3437**
[protocol no. MK-639-033] A Multi-Clinic Double-Blind Randomized Eighteen-Month Study in HIV-1 Seropositive Patients to Compare the Efficacy and Safety of MK-639 (800 mg q 8 h) and Zidovudine (200 mg q 8 h) Administered Concomitantly to MK-639 Alone and Zidovudine Alone	Lockey	5/4/1998	Closed - PI	Merck & Company, Inc.		**3791**
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Comparative Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Zafirlukast (20mg BID), in Subjects who are Currently Receiving Beta-Agonists Alone	Lockey	4/21/1998	Closed - PI	Glaxo Wellcome, Inc.		**4670**
12 Weeks Treatment with 250m g Roflumilast versus 500mg Roflumilast versus 10mg Montelukas versus Placebo in Patients with Asthma	Lockey		Closed - Never Opened	Byk Gulden Pharmaceuticals		**6075**
12 Weeks Treatment with 250m g Roflumilast versus 500mg Roflumilast versus Placebo Added to 200mg Fluticasone Propionate in Patients with	Lockey		Closed - Never Opened	Byk Gulden Pharmaceuticals		**6076**

Asthma						
A Double-Blind, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of L-753099 in Patients With COPD	Lockey		Closed - Never Opened	Merck & Company, Inc.		**5669**
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Virologic Activity, and Safety of Pleconaril (Oral Suspension) in the Treatment of Viral Respiratory Infection in Children 1 to 6 Years of Age	Lockey		Disapproved	ViroPharma, Inc.		**6324**
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Virologic Activity, and Safety of Pleconaril (Oral Suspension) in the Treatment of Viral Respiratory Infection in Children 7 to 12 Years of Age	Lockey		Disapproved	ViroPharma, Inc.		**6325**
A Randomized, Placebo-Controlled Study of the Safety and Immunologic Activity of a Single-Dose of Subcutaneous Recombinant Human Interleukin-12 (rhIL-12) Administered Concurrently with Cat Allergen in Patients Allergic to Cats	Lockey	1998	Closed - PI	Genetics Institute, Inc.		**4708**
A Randomized, Placebo-Controlled, Ascending-Dose Study of the Safety and Immunologic Activity of Nebulized Recombinant Human Interleukin-12 (rhIL-12) in Patients with Mild Asthma.	Lockey		Closed - Never Opened	Genetics Institute, Inc.		**5260**
[protocol no. Aradigm 97-01] 1997 Effectiveness of the SmartMist Asthma Management System Combined With Inhaled Fluticasone Propionate vs. Aerochamber with Fluticasone Propionate in Moderate and Severe Asthmatics (Aradigm 97-01 Ver.	Lockey		Closed - PI	Aradigm Corporation		**4572**

4/30/97)						
Efficacy and Safety of Combination Loratadine/Montelukast QD vs. its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis	Lockey		Closed - Never Opened	Schering-Plough Corporation		**5927**
Efficacy and Safety of Combination Loratadine/Montelukast QD vs. its Components vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis	Lockey		Closed - Never Opened	Schering-Plough Corporation		**5920**
The Efficacy of Disodium Octaborate Tetrahydrate (DOT) and Vacuum Cleaning in Lowering Dust House Mite Population and House Dust Mite Allergen Levels in Homes in Tampa, FL	Lockey		Closed - Never Opened	Division Sponsored		**100182**
A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti-Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium Dose Mometasone Furoate DPI and MDI Formulations in Adults and Adolescents with Persistent Allergic Asthma	Lockey		Closed - Never Opened	Schering-Plough Corporation		**106475**
[protocol no. CQAB149B2329] A 52-Week Treatment, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of Indacaterol (200 & 400 ug o.d.) in Patients with Chronic Obstructive Pulmonary Disease Using Open Label Tiotropium (18 ug o.d.) As An Active Control - CQAB149B2329	Lockey		Closed - Never Opened	Novartis Pharmaceutical Corporation		**104337**

A Comparative Double-Blind, Double-Dummy Study of Desloratadine (DL) 4mg Once Daily, Cetirizine 10mg Once Daily and Placebo Once Daily in Patients with Chronic Idiopathic Urticaria (CIU)	Lockey		Closed - Never Opened	Integrated Therapeutics Group, Incorporated		**102386**
[protocol no. XRP1526B/3030] A Multicenter, Randomzied, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160ug Administered for 12 Weeks Either In A Once-Daily Regimen in the Morning (160ug qd AM) Or In A Twice Daily Regimen (80 ug bid) in Adults and Adolescents with Mild to Moderate Persistent Asthma Treated Previously With Inhaled Corticosteriods - XRP1526B/3030	Lockey		Closed - Never Opened	Aventis		**103863**
A One Week, Double-Blind, Randomized, Placebo-Controlled Dose-Confirming Study to Determine the Efficacy and Safety of Oxis™ Turbuhaler® Administered to Children with Asthma	Lockey		Closed - Never Opened	AstraZeneca Ltd.		**6119**
A One Week, Double-Blind, Randomized, Placebo-Controlled, Dose-Confirming Study to Determine the Efficacy and Safety of Oxis™ Turbuhaler® Administered to Adults and Adolescents with Asthma	Lockey		Closed - Never Opened	AstraZeneca Ltd.		**6112**
[protocol no. FFA109684] A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily	Lockey		Closed - Never Opened	GlaxoSmithKline		**106484**

Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy						
[protocol no. FFA20003] 2006 A Randomized Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 200mcg, 400mcg, 600mcg and 800mcg Administered Once Daily in the Morning and Fluticasone Propionate 500mcg BID via DISCUS Inhalation Powder Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (>=12 years old) with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy - FFA20003	Lockey		Closed - Never Opened	GlaxoSmithKline		**103874**
[protocol no. FFA100240] 2006 A Randomized Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 25mcg, 50mcg, 100mcg and 200mcg Administered Once Daily in the Morning and Fluticasone Propionate 100mcg BID via DISKUS Inhalation Powder Compared with Placeby for 8 Weeks in Adolescent and Adult Subjects (=12 years old) with Persistent Asthma Symptomatic on NON-ICS Therapy - FFA100240	Lockey		Closed - Never Opened	GlaxoSmithKline		**103875**
[protocol no. BY217/M2-023] A Randomized, Controlled Study of Roflumilast (250 mcg and 500 mcg)	Lockey	2005	Closed - PI	Altana Pharma		**102043**

versus Placebo in Patients with Asthma						
[protocol no. D5896C00001 D5 GEMINI] A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Single-Dummy, Multicenter, 12 Week Study to Assess the Efficacy and Safety of SYMBICORT® pMDI 160/4.5 ug x 2 Actuations Once-Daily (QD) Compared to SYMBICORT pMDI 80/4.5 ug x 2 Actuations QD, SYMBICORT pMDI 80/4.5 ug x 2 Actuations Twice-Daily (BID) and to Budesonide pMDI 160 ug x 2 Acutations QD in Asthmatic Subjects 12 Years of Age and Older	Lockey	2006	Closed - PI	AstraZeneca Ltd.		**102637**
[protocol no. FFU105927] Never started A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, One-Week, Cross-Oer, Multi-Center Study to Evaluate the Efficacy and Experience of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200 mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis (FF105927)	Lockey		Closed - PI	GlaxoSmithKline		**105988**
[protocol no. CQAB149B2205] A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Multiple Dose (7 days) Dose-Ranging Study, To Assess the Efficacy and Safety of 4 Doses of QAB149 (50, 100, 200 & 400 ug) Delivered via a Multiple Dose Inhaler and 1 Dose of QAB149 (400 ug) Delivered via a Single Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD)	Lockey	2006	Closed - PI	Novartis Pharmaceutical Corporation		**102698**

- CQAB149B2205						
[protocol no. SKY 2028-004] 2008 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Stratified, Multi-Center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 100/10ug or 250/10ug twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Placebo or Fluticasone (250ug twice daily) and Formoterol (10ug twice daily) Alone in Adolescent and Adult Patients with Moderate to Severe Asthma - sky2028-004	Lockey		Closed - Never Opened	Skye Pharma, Inc.		**104408**
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis	Lockey		Closed - Never Opened	GlaxoSmithKline		**106532**
[protocol no. FFR100010] A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects ages 2 to <12 Years with Seasonal Allergic	Lockey	2005	Closed - PI	GlaxoSmithKline		**103386**

Rhinitis (SAR)						
[protocol no. FFR30002] **A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mg for 4 weeks in Adult and Adolescent Subjects (=>12 years of age) with Perennial Rhinitis**	Lockey	2005	Closed - PI	GlaxoSmithKline		**103264**
[protocol no. SD-0040764] **A Randomized, Partly Blinded, Multicenter, Parallel Study Comparing the Efficacy and Safety of PULMICORT RESPULES® (budesonide inhalation suspension) at 0.5 mg, QD, 1.0 mg QD, 1.0 mg BID, 2.0 mg BID and PULMICORT TURBUHALER® (budesonide) at 400 mcg BID in Adolescents (12 Years of Age and Older) and Adults with Moderate to Severe Asthma**	Lockey	2004	Closed - PI	AstraZeneca Ltd.		**102357**
[protocol no. SFA100316] **A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects with Activity Induced Bronchospasm**	Lockey	2005	Closed - PI	GlaxoSmithKline		**101998**

[protocol no. MRE0470P-203] A Two-Part Study to Evaluate the Safety of Binodenoson (MRE0470) in Adult Subjects With Mild, Intermittent Asthma	Lockey	2003	Closed - PI	King Pharmaceuticals Research and Development, Inc.		**101766**
Phase I, Open-Label Investigation of Safety and Pharmacokinetics of Lyophilized Korean Green Cross Intravenous Immune Globulin 5% Solution in Patients with Primary Immunodeficiency Disorders	Lockey		Closed - Never Opened	Unassigned		**6102**
Procalcitonin Level as a Diagnostic Aid in Acute Bacterial Sinusitis	Lockey		Closed - Never Opened	Default Sponsor		**106964**
[protocol no. A2-8397-CAT] Prospective Validation Study of the Chronic Obstructive Pulmonary Disease Assessment Test (CAT) in Stable and Exacerbating Patients	Lockey		Closed - Never Opened	GlaxoSmithKline		**107621**
Rhinitis and Sinusitis in Asthma	Lockey		Closed - Never Opened	American Lung Association		**103260**
[protocol no. SARA] Study of Acid Reflux and Asthma (SARA)	Lockey	2009	Closed - PI	American Lung Association		**102756**
Systemic Reactions in Allergen Immunotherapy	Lockey	2008	Closed - PI	Division Sponsored		**107333**
The Leukotriene Modifier Or Corticosteroids or Corticosteroid-Salmeterol Trial (The LOCCS Trial)	Lockey	2005	Closed - PI	American Lung Association		**100966**

[protocol no. Formoterol 37-3027, proj. no. 843-32] A double-blind, randomized, parallel-group, placebo-controlled dose response study of formoterol Turbuhaler 6, 12, and 24 mcg administered twice daily in patients with asthma	Lockey	1994	Closed	Astra, USA		**3428**
HZA106853: A dose-ranging study of vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy	Lockey	04/09/2012	Approved, Open	GlaxoSmithKline		**20120370**
GB27862: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA WHO ARE ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION	Lockey	03/12/2012	Approved, Open	Genentech (a member of the Roche group)		**20120172**
SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma	Lockey	01/25/2012	Approved, Open	GlaxoSmithKline Research & Development Limited		**20112136**
SAS115358: A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma	Lockey	11/18/2011	Approved, Open	GlaxoSmithKline Research & Development Limited		**20111924**

FFR101782: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis	Lockey	2007	Closed	GlxoSmithKline		**20072255**
HGT-FIR-086: A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents with Hereditary Angioedema	Lockey	10/13/2011	Approved, Open	Shire Orphan Therapies, Inc		**20111381**
HGT-FIR-054: A Phase III Randomized Double-blind, Placebo-controlled Multicenter Study of Icatibant for Subcutaneous Injection in Patients with Acute Attacks of Hereditary Angioedema (HAE)	Lockey	2009	Closed	Jerini US, Inc.		**20090365**
A6631029: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 FOR 12 WEEKS IN ADULTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ON A BACKGROUND OF SALMETEROL ZINOFOATE/FLUTICASONE PROPIONATE COMBINATION	Lockey	08/16/2011	Approved, Open	Pfizer Limited		**20111229**

HZC113782: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease	Lockey	06/29/2011	Approved, Open	GlaxoSmithKline		**20110383**
FFA109684: A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy	Lockey	2008	Closed	GlaxoSmithKline		**20080317**
ACT11457: A randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of SAR231893/REGN668 administered subcutaneously (SC) once weekly for 12 weeks in patients with persistent moderate to severe eosinophilic asthma who are partially controlled/uncontrolled by inhaled corticosteroid (ICS) plus long-acting beta2 agonist (LABA) therapy	Lockey	08/16/2011	Approved, Open	Sanofi-aventis, US, Inc.		**20110248**
C1 1310: A Phase IIIb randomized, double-blind, placebo-controlled study with an open-label extension evaluating the efficacy, safety and immunogenicity of recombinant human C1 inhibitor for the treatment of acute attacks of angioedema in patients with HAE	Lockey	01/04/2011	Approved, Open	Pharming Technologies B.V.		**20102041**

[protocol no. C 1205-01] **C 1205-01: A randomized, placebo-controlled, double-blind Phase II study of the safety and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema**	Lockey	2010	Closed	Pharming Technologies, B.V.		**20051760**
P06476: A Randomized, Evaluator-Blind, Crossover, Single Dose Study of the Bronchodilator Effect of Formoterol Fumarate in Combination With Mometasone Furoate Metered Dose Inhaler Delivered With and Without a Spacer Versus Placebo and Foradil® Aerolizer® in Children With Persistent Asthma	Lockey	2010	Closed	Schering Plough Research Institute, a Division of Schering Corporation		**20102021**
[protocol no. MI-CP186] **A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563, A Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, on Asthma Control Following Acute Exacerbations in Adults**	Lockey	2009	Closed	MedImmune		**20090964**
[protocol no. 205.452] **A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler®**	Lockey	2010	Closed	Boehringer Ingelheim Pharmaceuticals, Inc.		**20100683**

[protocol no. 1184.15] **1184.15: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double-blind, parallel group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5µg/25 µg) Inhalation Powder in the morning (PE capsule via tiotropium/salmeterol HandiHaler®), Tiotropium (18 µg) Inhalation Powder in the morning (gelatin capsule via Spiriva® HandHaler®),Salmeterol Inhalation (25 µg) Powder in the morning and evening (PE capsule via tiotropium/salmeterol HandiHaler®) and Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalation Powder in the morning (PE capsule via tiotropium /salmeterol HandiHaler®) plus Salmeterol (25 µg) Inhalation Powder in the evening (PE capsule via tiotropium/salmeterol HandiHaler®) in patients with COPD**	Lockey	2008	Closed	Boehringer Ingelheim Pharmaceuticals, Inc.		**20080635**
[protocol no. A7881013] **A7881013: A PHASE 2B, PARALLEL, DOUBLE BLIND, DOUBLE DUMMY, ACTIVE COMPARATOR AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND EFFICACY OF 6-WEEK QD ADMINISTRATION OF PF-00610355 CRC-749 DPI IN PATIENTS WITH MODERATE COPD**	Lockey	2010	Closed	Pfizer		**20100640**
[protocol no. DX-88/24] **DX-88/24: A Phase 4, Long-Term Observational Safety Study to Evaluate Immunogenicity and Hypersensitivity with Exposure to KALBITOR (ecallantide) for the Treatment of Acute**	Lockey	05/10/2010	Approved, Open	Dyax Corp.		**20092375**

Attacks of HAE						
[protocol no. DX-88/19] **DX-88/19: Patient Long Term Continuation of DX-88 (Ecallantide) for acute Hereditary or Acquired Angioedema Attacks**	Lockey	2006	Closed	Dyax Corp.		**20062187**
[protocol no. DX-88/14] **DX-88/14: Evaluation of DX-88's Effects in Mitigating Angioedema A double-blind, placebo-controlled study followed by a repeat dosing phase to assess the efficacy and safety of DX-88 (recombinant plasma kallikrein inhibitor) for the treatment of acute attacks of Hereditary Angioedema**	Lockey	2005	Closed	Dyax Corp.		**20052247**
[protocol no. MI CP-143] **A phase 2A, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety and effect on exercise challenge testing of multiple fixed subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in adults with stable asthma and exercise-induced bronchoconstriction**	Lockey	2009	Closed	MedImmune		**20080592**
[protocol no. 091-061] **091-061: A Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 µg and 25 µg Arformoterol Tartrate Inhalation Solution BID in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease**	Lockey	2007	Closed	Sepracor		**20052090**

[protocol no. ADA103578] ADA103578: A multicenter, randomized, double-blind, triple-dummy, placebo-controlled, parallel group, four-week study assessing the efficacy of fluticasone propionate aqueous nasal spray 200 mcg QD versus montelukast 10 mg QD in adolescent and adult subjects with asthma and seasonal allergic rhinitis who are receiving ADVAIR Diskus 100/50 mcg BID or placebo BID	Lockey	2007	Closed	GlaxoSmithKline		**20051857**
[protocol no. DX-88/20] DX-88/20: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of DX-88 (Ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema.	Lockey	2008	Closed	Dyax Corp.		**20062444**
[protocol no. FFA109687] FFA109687: A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 100mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non-Steroidal Asthma Therapy	Lockey	2008	Closed	GlaxoSmithKline		**20080274**
[protocol no. B2C111045] B2C111045: A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD	Lockey	2008	Closed	GlaxoSmithKline		**20080240**

[protocol no. MEE103219] MEE103219: A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years	Lockey	2008	Closed	GlaxoSmithKline		**20061258**
[protocol no. VAL-P-03-103] VAL-P-03-103: Interview study to explore the content validity of visual analogue scales to assess severity of hereditary angioedema (HAE) in adults in the USA and Italy	Lockey	2009	Closed	Pharming Technologies B.V.		**20091584**
[protocol no. CQAB149B2351] CQAB149B2351: A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150µg once daily with open label tiotropium 18µg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease	Lockey	2009	Closed	Novartis Pharmaceutical corporation		**20090658**
[protocol no. SB 205312/070] A multi-center, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of two doses of SB205312 administered as an oral suspension (75 mg BID and 150 mg BID) for 12 weeks in pediatric outpatients with asthma	Lockey	1997	Closed	SmithKline Beecham		
[protocol no. LO269] A double-blind, parallel, multicenter study of the safety and efficacy of citirizine and clemastine versus placebo in the treatment of season allergic rhinitis in children	Lockey	1993	Closed	Pfizer		

[protocol no. P94-142-17] **A phase IV, double-blind, placebo-controlled, double-dummy, comparison of clinical efficacy and safety of Vanceril MDI versus Azmacort MDI in adult asthmatics**	Lockey	1995	Closed	Schering		
[protocol no. PDA-641/0805-A-205-US] **A comparison of the safety and efficacy of two oral doses of PDA-641 10 mg and 30 mg TID and placebo in mild to moderate asthmatics**	Lockey	1996	Closed	Wyeth-Ayerst		
[protocol no. MK 031-01] **A multicenter, double-blind, randomized, parallel group study comparing the clinical effect of MK-0476 and placebo in patient with chronic asthma**	Lockey	1994	Closed	Merck Research Laboratories		
[protocol no. Rhinocort 05-3046-3047] **A randomized, open-label, comparison of rhinocort budesonide aqua pump spray versus NASALCROM (cromolyn sodium)in treatment of children with perennial rhinitis**	Lockey	1995	Closed	Astra USA		
[protocol no. M94199] **A long-term, surveillance study of Zileuton + usual care versus usual care in patients with asthma**	Lockey	1995	Closed	Abbott Laboratories		
[protocol no. PJPR0053] **A double-blind, randomized study comparing the efficacy and safety of Fexofenadine and placebo in black patients with seasonal allergic rhinitis**	Lockey	1996	Closed	Hoechst-Marion Roussel, Inc.		
[protocol no 9188IL-0029] **A multicenter, double-blind, placebo-controlled study of Accolate in mild to moderate asthmatic patients needing chronic treatment 13-week efficacy and up to 1 year open-label safety study extension**	Lockey	1993	Closed	ICI Pharmaceuticals Group		

[protocol no. FEPROO51] A placebo-controlled, double-blind, randomized, parallel study comparing duration and action and safety and efficacy of four dose strengths of Terfenadine in the treatment of fall allergies	Lockey	1993	Closed	Marion Merrill Dow, Inc.		
[protocol no. FLD-402] A randomized, double-blind, double-dummy, parallel-group comparative trial of inhaled fluticasone propionate rotadisk via Disk haler 250 mcg BID versus azmacort oral inhaler 200 mcg QID versus placebo in adolescents and adult subjects with moderate chronic asthma	Lockey	1994	Closed	Glaxo, Inc.		
[protocol no. SLGA5013] A randomized, double-blind, placebo-controlled, parallel-group evaluation of the effects of salmeterol on methacholine induced bronchial hyperesponsiveness over 24-weeks in adolescents and adults subjects with asthma	Lockey	1995	Closed	GlaxoSmithKline		
[protocol no. Miles] A double-blind, randomized, placebo-controlled trial in the safety and efficacy of oral bay x 1005 100mg BID versus 250mg BID versus 500mg BID versus placebo BID for six-weeks in patients with asthma	Lockey	1994	Closed	Bayer		
[protocol no. Accolate 579394] A multicenter, double-blind efficacy trial to compare accolate given at 160mg per day with placebo over 13-weeks in subjects with chronic severe asthma	Lockey	1998	Closed	Zeneca Pharmaceuticals		

[protocol 847] **A randomized, double-blind, parallel-comparison of atrovent nasal spray 0.06% and 0.12% 84mcg versus 168 mcg per nostril respectively versus placebo BID in allergic perennial allergic rhinitis**	Lockey	1991	Closed	Boehringer Ingelheim		
[protocol no. 94-433] **A clinical use study comparing nasalcrom nasal solution 4% to placebo nasal solution in treatment of the symptoms associated with seasonal allergic rhinitis**	Lockey	1995	Closed	Wallace		
[Protocol no. GS9310] **Quarterly long-term follow-ups on GS93107: An open–label study of the safety and efficacy of cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS**	Lockey	1998	Closed	GILEAD Sciences		
[protocol no. SLGA 4004/4005] **A randomized, double-blind, double-dummy, comparative clinical trial of a 12-week course of salmeterol xinafoate versus ipratropium Bromide versus placebo PRN ventolin in subjects with chronic obstructive pulmonary disease**	Lockey	1995	Closed	Glaxo Wellcome		
[protocol no. DFI2588, proj. no. 2446] **A multi-center, double-blind, placebo-controlled, dose ranging study to assess and compare the activity of an oral administration FR27417-2.5, 10 and 30mg once a day during 12 weeks in moderate asthmatic patients**	Lockey	1995	Closed	Sanofi/Innovex, Inc.		
[protocol no. V211-017-0030] **V211-017-0030: A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live in Patients on Chronic/Maintenance Corticosteroids**	Lockey	2010	Closed	Merck & Co.		

[protocol no. 048-076] **Terfenadine Urticaria Study**	Lockey	1986	Closed, destroyed	Merrill-Dow		
[protocol no. 85-N-0039] **Cetirizine Urticaria Study**	Lockey	1980	Closed, destroyed	Pfizer		
[protocol no. ANC-MD-07-000] **A One-Year, Open-Label Study to Evaluate the Safety of HFA Flunisolide in Children with Mild to Moderate Asthma**	Lockey	1999	Closed	Forest Research Institute		
[protocol no. MO16455/4092] **The effects of once daily dosing of fexofenadine HCl in patients with seasonal allergic rhinitis and concomitant mild to moderate asthma**	Lockey	2002	Closed	Hoechst Marion Roussel		
[protocol no. C94-092-11] **Safety and Efficacy of Mometasone Furoate Nasal Spray vs. Placebo in the treatment of Elderly patients with Perennial Rhinitis**	Lockey	1994	Closed	Schering-Plough Corporation		
[protocol no. M90-460] **5-Lipoxygenase Inhibitor Zileuton (Abbott-64077): A Phase II Study on the Safety and Efficacy of Zileuton (ABBOTT-64077), 800mg B.I.D. or 600mg Q.I.D. versus Placebo in the Treatment of Moderate Asthma**	Lockey	1990	Closed	Abbott Laboratories		
[protocol no. C88-069-04] **The Efficacy of SCH 37224 in Mild to Moderate Asthma**	Lockey	1988	Closed	Schering Corp.		

[protocol no. 888-201-3] **A Multicenter, Double-Blind, Three Month Study of the Comparative Efficacy and Safety of Procaterol and Albuterol Aerosol Administered QID in Outpatients with Reversible Bronchial Airway Obstruction**	Lockey	1989	Closed	Parke-Davis Pharmaceutical		1685
[protocol no. RG-5003-601] **A Multi-Center, Single-Blind, Randomized, Parallel Study Evaluating the Safety and Efficacy of a Once-A-Day Evening Dosing of SLO-BID™ Gyrocaps® (theophylline, anhydrous) vs. Theo-Dur® Tablets (theophylline, anhydrous) B.I.D. in the Treatment of Nocturnal Asthma**	Lockey	1993	Closed	Rorer Pharmaceutical Corporation		
[protocol no. AU-115, Ridaura] **Auranofin versus Placebo in the Treatment of Steroid-Dependent Asthma**	Lockey	1989	Closed	Smith Kline & French Laboratories		
[protocol no. 9188IL/0028] **A Multicenter, Randomized, Double-Blind Study to Compare the Effect of Oral Doses of ICI 204,219 with Placebo Over 13 weeks in Subjects with Mild to Moderate Asthma**	Lockey	1992	Closed	Zeneca Pharmaceuticals Group		
[protocol no. SLGA 4004/4005] **A randomized, double-blind, double-dummy, comparative clinical trial of a 12-week course of salmeterol xinafoate versus ipratropium Bromide versus placebo PRN ventolin in subjects with chronic obstructive pulmonary disease**	Lockey	1995	Closed	GlaxoSmithKline		

[protocol no. 01029] Randomized, Multiple-Dose, Double-Blind Comparison of COMBIVENT® and Ventolin® in a Four Week, Parallel Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)	Lockey	1993	Closed	Boehringer Ingelheim		
[protocol no. 120-01/SNG 477] A Randomized. Double-Blind, Multicenter Study to Evaluate the Effect of Adding Either Montelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics	Lockey	2000	Closed	Merck & Co.		
[protocol no. M/5900/0003] The treatment of AIDS associated cachexia patients with halotestin tablets	Lockey	1992	Closed	Upjohn Company		
[protocol no. BW825] Burroughs Wellcome Study	Lockey	1984	Closed	Burroughs Wellcome		
Double-blind parallel study (Rotcap Study) and subcutaneous injectable study	Lockey	1984	Closed	Glaxo		
[protocol no. AI414-144] Multicenter, Three-Arm, Comparative Study of Cefprozil 250mg BID or 500mg BID versus Amoxicillin/Clavulanate potassium 500mg TID in the treatment of Acute and Uncomplicated Maxillary Sinusitis	Lockey	1993	Closed	Bristol Myers Squibb		
[protocol no. UNX-2405] A Comparison of the Safety and Efficacy of the 2 Immune Globulin Intravenous Human Preparations (Unigam and Gammar ID) in Primary Immunodeficiency Patients	Lockey	1993	Closed	Univax Biologics		2881

Bronkometer **Isoepharine Six-Week Trial of Pediatric Asthmatic Patients PD-663**	Lockey	1986	Closed	Sterling Winthrop		
[protocol no. SEPR0051] **A placebo-controlled, double-blind, randomized, parallel study comparing the duration of action in safety and efficacy of four dose strengths of Terfenadine in the treatment of fall allergies**	Lockey	1993	Closed	Marion Merrill Dow		
[protocol no. FLI-301] **A randomized, double-blind, comparative trial of two doses of inhaled Fluticasone Proprionate and Placebo in Adolescent and Adult Patients with Mild to Moderate Asthma**	Lockey	1990	Closed	Glaxo SmithKline		
[protocol PHR-305] **A double-blind, double-dummy, parallel group evaluation of the clinical equivalent of albuterol aerosol delivery through the standard BK300 valve or through the redesigned BK356 valve**	Lockey	1991	Closed	Glaxo SmithKline		
Cetirizine **A double-blind, parallel, multicenter study of the safety and efficacy of Cetirizine 5mg versus Cetirizine 10mg versus Astemizole 10mg in the treatment of Seasonal Allergic Rhinitis**	Lockey	1992	Closed	Pfizer		
[protocol no. RG5016-112] **An efficacy trial, comparable plasma concentrations of Triamcinolone acetonide given by inhalation (Azmacort) and intramuscular injection (Kenalog-40) in the management of moderate asthmatics**	Lockey	1989	Closed	Rorer		
[protocol no. C91-218-05] **Proventil Repetabs for the prevention of the nocturnal symptoms of asthma**	Lockey	1992	Closed	Schering Plough		

[protocol no. FLTA 4031] **A randomized, double-blind, double-dummy, placebo-controlled, parallel group, comparative study of inhaled fluticasone proprionate 88mcg BID versus Zafirlukast 20 mg BID in subjects who currently receiving beta agonists alone**	Lockey	1997	Closed	Glaxo Wellcome		
[protocol no. SMART, SMG 477] **A randomized, double-blind, multicenter to evaluate the effect of adding either montelukast sodium or salmeterol xinafoate to inhaled fluticasone on adult asthmatics**	Lockey	2000	Closed	Merck		
[protocol no. SLGA 5007] **A double-blind, parallel group evaluation of salmeterol versus placebo in the treatment of nocturnal asthma**	Lockey	1994	Closed	Glaxo SmithKline		
[protocol noABS-AS-304] **A 12-week comparison of the efficacy and safety and steady-state Pharmacokinetics of albuterol Spiromax® and placebo in subjects 12 years and older with persistent asthma with steady state pharmacokinetics assessments**	Lockey	2012	Closed	Teva Pharmaceuticals		20122022
[protocol no. VR506/2/004] **A randomized double-blind, parallel group, dose-ranging study to evaluate the efficacy and safety of three different total daily doses of fluticacasone propionate inhaled from a new dry powder inhaler in subjects with severe persistent asthma requiring oral corticosteroid therapy**	Lockey	2012	Open	Vectura Limited (Vectura")		20121078

[protocol no. OPN-FLU-NP-3101] A 16-Week Randomized Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 µg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects with Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety.	Lockey	2012	Open	OptiNose US, Inc.		20121023
[protocol no. KB003-04] A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety Tolerability, and Efficacy of KB003 in Subjects with Asthma Inadequately Controlled by Corticosteroids.	Lockey	2012	Closed	KaloBios Pharmaceuticals, Inc.		20120727
[protocol no. A6631033 A Phase 2B, Randomized, Double-Blind, Double-Dynnt, Pkacevi-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once,-Daily Orally Administered PH-797804 for 12 Weeks in Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) on a Background of Tiotropium Bromide.	Lockey	2012	Closed	Pfizer, Inc/		20120635
[protocol no. HZA 106853] A dose-ranging study of vilanterol (VI) inhalation powder in children aged 5-11years with asthma on a background of inhaled corticosteroid therapy.	Lockey	2012	Open	GlaxoSmithKline		20120370
[protocol no. HZA SAS115359 A Safety and Effecacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone	Lockey	2011	Closed	GlaxoSmithKline Research &		20112136

Propionate in the Treatment of Adolescent and Adult Subjects with Asthma.				DevelopmentLimited		
[protocol no. SAS115358] A 6-Month Safety and Benefit Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatmnet of 6,200 Pediatric Subjects 4-11 years Old with Persistent Asthma.	Lockey	2011	closed	GlaxoSmithKline Research & DevelopmentLimited		20111924
[protocol no. HGT-FIR-086] A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents with Hereditary Angioedema	Lockey	2011	Open	Shire Orphan Therapies, Inc.		20111381
[protocol no. A6631029] A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Daily Orally Administered PH-797804 for 12 Weeks in Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) on a Background of Salmeterol Xinofoate/Fluticasone Propionate Combination.]	Lockey	2011	Closed	Pfizer Limited		20111229
[protocol no. HZC113782] A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25 mcg with Placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary disease (COPD) and a History o for at Increased Risk for Cardiovascular Disease.	Lockey	2011	Open	GlaxoSmithKline		20110383

[protocol no. C1 1310] **A Phase IIIb Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients with HAE.]**	Lockey	2010	Closed	Pharming Technologies B.V.		20102041
[protocol no. MI-CP220/D3250L00001] **A Phase 2b, Dose-Ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults with Uncontrolled Asthma.**	Lockey	2010	Closed	Medimmune, LLC, an affiliateof AstraZeneca AB		20101198
[protocol no. BDB-AS-301] **12 week study to assess the efficacy and safety of 320 or 640 mcg/day of Beclomethasone Dipropionate delivered via BAI or MDI in patients 12 and up with persistent asthma**	Lockey	2013	Approved/ Open	Teva Pharmaceuticals		201402076
[protocol no. WB28183] phase 3 study to assess the efficacy, safety and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma who are on ICS and second controller medication	Lockey	2013	Approved/ Opne	Roche Genentech		28264/18
[protocol no. DX-2930-02] **Phase 1b study to assess safety, tolerability and pharmacokinetics of DX-2930i HAE subjects**	Lockey	2013	Approved/ Open	Dyax		20140517
[Protocol no. DX-88/24] **A Phase 4, Long-Term Observational Safety Study to Evaluate Immunogenicity and Hypersensitivity with Exposure to KALBITOR (ecallantide) for the Treatment of Acute Attacks of HAE.**	Lockey	2009	Closed	Dyax Corp.		20092375

The Study of Soy Isoflavones in Asthma (SOYA)	Lockey	2009	Closed	American Lung Association		Pro00000006
Asthma Patient Registry	Lockey	2010	Open	American Lung Association		108273
Long Acting Beta Agonist Stepdown Study (LASST)	Lockey	2012	Closed to Enrollment, Data Analysis	American Lung Association		Pro00007478
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients with Asthma (CPAP)	Lockey	2012	Closed	American Lung Association		Pro00009173
"SAPS: Smoking Asthmatics Pilot Study; Smoking Cohort Study."	Lockey	2013	Closed	American Lung Association		Pro00011354
Anxiety and COPD Evaluation (ACE)	Lockey	2015	Open	American Lung Association		Pro00021632
Resistant Airway Obstruction in Children (REACH)	Lockey	2015	Closed To Enrollment	American Lung Association		Pro00021221
[protocol no. C1-3201] Study to Evaluate the Efficacy and Safety of Recombinant Human C1 Inhibitor in the Prophylaxis of Angioedema Attacks in Patients with Hereditary Angioedema	Lockey	2014	Open	Pharming		29877/2
[protocol A9111007] STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-03715455 ADMINISTERED TWICE DAILY BY INHALATION FOR 12 WEEKS IN SUBJECTS WITH PERSISTENT	Lockey	2014	Closed	Pfizer		201405155

MODERATE TO SEVERE ASTHMA						

RESEARCH STUDIES 2017 – FEBRUARY 12, 2019

A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THREE DOSES OF ORVEPITANT IN SUBJECTS WITH CHRONIC REFRACTORY COUGH

OPEN-LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS WA40169

A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED ≥6 MONTHS TO <6 YEARS WITH SEVERE ATOPIC DERMATITIS R668-AD-1539

AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS ≥6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS R668-AD-1434

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, ≥6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS R668-AD-1652

Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations (PREPARE)

A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS B7451014

Chronic Refractory Cough Cohort Study (COCO)

Losartan Effects on Emphysema Progression (LEEP)

Parental Response Using a Daily Digital Diary to Capture Respiratory Symptoms in Young Children with Recurrent Respiratory Tract Illnesses (American Lung Association [ALA] Novel Digital Diary [**ANDDi**])

Asthma BMI Baseline Study (ABBS)

A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines CQGE031C2302

A randomized, subject- and investigator-blinded, placebo-controlled, multi-center, multiple dose study to assess the efficacy and safety of CJM112 in patients with inadequately controlled moderate to severe asthma CCJM112X2204

A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT AND DOSE-RANGING STUDY OF GDC-0853 IN PATIENTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA (CSU) GS39684

A PHASE II OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF FENEBRUTINIB IN PATIENTS PREVIOUSLY ENROLLED IN A FENEBRUTINIB CHRONIC SPONTANEOUS URTICARIA STUDY GS40868

HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention against Acute Attacks of Hereditary Angioedema (HAE) DX-2930-04

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE) ARC011

A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY ARC008

PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY ARC004

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years (RAMSES) ARC007

A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB AS ADJUNCT TO AR101-CODIT (PEANUT ORAL IMMUNOTHERAPY) R668-ALG-16114

A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PEDIATRIC PATIENTS WITH PEANUT ALLERGY R668-ALG-1702